Cargando…
The comparison between Caprini and Padua VTE risk assessment models for hospitalised cancer patients undergoing chemotherapy at the tertiary oncology department in Poland: is pharmacological thromboprophylaxis overused?
AIM OF THE STUDY: Thromboprophylaxis in cancer patients during hospitalization reduces the risk of venous thromboembolism (VTE). MATERIAL AND METHODS: To assess the underuse and the overuse of thromboprophylaxis in cancer patients at a tertiary oncology department, we retrospectively analyzed 1983 c...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909728/ https://www.ncbi.nlm.nih.gov/pubmed/29692661 http://dx.doi.org/10.5114/wo.2018.74391 |
_version_ | 1783315947148279808 |
---|---|
author | Łukaszuk, Robert F. Dolna-Michno, Justyna Plens, Krzysztof Czyżewicz, Grzegorz Undas, Anetta |
author_facet | Łukaszuk, Robert F. Dolna-Michno, Justyna Plens, Krzysztof Czyżewicz, Grzegorz Undas, Anetta |
author_sort | Łukaszuk, Robert F. |
collection | PubMed |
description | AIM OF THE STUDY: Thromboprophylaxis in cancer patients during hospitalization reduces the risk of venous thromboembolism (VTE). MATERIAL AND METHODS: To assess the underuse and the overuse of thromboprophylaxis in cancer patients at a tertiary oncology department, we retrospectively analyzed 1983 consecutive hospitalizations of 498 cancer patients who received chemotherapy from October 2016 to May 2017. The Padua prediction score (≥ 4 points) and Caprini risk assessment (≥ 5 points) were used to identify patients at high risk of VTE. RESULTS: The majority of individuals (n = 363, 72.9%) suffered from advanced lung cancer. We found that 419 (84.14%) patients received thromboprophylaxis with enoxaparin 40 mg qd,including 181 (43.2%) individuals using concomitant mechanical thromboprophylaxis. As few as 44 (8.8%) and 11 (2.2%) patients did not receive thromboprophylaxis despite high VTE risk based on the Caprini risk assessment and Padua prediction score, respectively (p < 0.001). The number of patients without high risk of VTE, who received pharmacological thromboprophylaxis, was higher when the Padua prediction score was used compared with the Caprini risk assessment (n = 391 [78.5%] vs. n = 210 [42.2%], respectively; p < 0.001). Three patients (0.6%) experienced vascular events during hospital stay, including one symptomatic deep vein thrombosis. No major bleeding was observed. Predictors of thromboprophylaxis overuse were as follows: previous VTE and abnormal pulmonary function for both scales. CONCLUSIONS: This study shows that thromboprophylaxis in cancer in patients undergoing chemotherapy is suboptimal in Poland in part due to the use of various VTE risk scores yielding discrepant results in everyday practice. |
format | Online Article Text |
id | pubmed-5909728 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-59097282018-04-24 The comparison between Caprini and Padua VTE risk assessment models for hospitalised cancer patients undergoing chemotherapy at the tertiary oncology department in Poland: is pharmacological thromboprophylaxis overused? Łukaszuk, Robert F. Dolna-Michno, Justyna Plens, Krzysztof Czyżewicz, Grzegorz Undas, Anetta Contemp Oncol (Pozn) Original Paper AIM OF THE STUDY: Thromboprophylaxis in cancer patients during hospitalization reduces the risk of venous thromboembolism (VTE). MATERIAL AND METHODS: To assess the underuse and the overuse of thromboprophylaxis in cancer patients at a tertiary oncology department, we retrospectively analyzed 1983 consecutive hospitalizations of 498 cancer patients who received chemotherapy from October 2016 to May 2017. The Padua prediction score (≥ 4 points) and Caprini risk assessment (≥ 5 points) were used to identify patients at high risk of VTE. RESULTS: The majority of individuals (n = 363, 72.9%) suffered from advanced lung cancer. We found that 419 (84.14%) patients received thromboprophylaxis with enoxaparin 40 mg qd,including 181 (43.2%) individuals using concomitant mechanical thromboprophylaxis. As few as 44 (8.8%) and 11 (2.2%) patients did not receive thromboprophylaxis despite high VTE risk based on the Caprini risk assessment and Padua prediction score, respectively (p < 0.001). The number of patients without high risk of VTE, who received pharmacological thromboprophylaxis, was higher when the Padua prediction score was used compared with the Caprini risk assessment (n = 391 [78.5%] vs. n = 210 [42.2%], respectively; p < 0.001). Three patients (0.6%) experienced vascular events during hospital stay, including one symptomatic deep vein thrombosis. No major bleeding was observed. Predictors of thromboprophylaxis overuse were as follows: previous VTE and abnormal pulmonary function for both scales. CONCLUSIONS: This study shows that thromboprophylaxis in cancer in patients undergoing chemotherapy is suboptimal in Poland in part due to the use of various VTE risk scores yielding discrepant results in everyday practice. Termedia Publishing House 2018-04-03 2018 /pmc/articles/PMC5909728/ /pubmed/29692661 http://dx.doi.org/10.5114/wo.2018.74391 Text en Copyright: © 2018 Termedia Sp. z o. o. http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Original Paper Łukaszuk, Robert F. Dolna-Michno, Justyna Plens, Krzysztof Czyżewicz, Grzegorz Undas, Anetta The comparison between Caprini and Padua VTE risk assessment models for hospitalised cancer patients undergoing chemotherapy at the tertiary oncology department in Poland: is pharmacological thromboprophylaxis overused? |
title | The comparison between Caprini and Padua VTE risk assessment models for hospitalised cancer patients undergoing chemotherapy at the tertiary oncology department in Poland: is pharmacological thromboprophylaxis overused? |
title_full | The comparison between Caprini and Padua VTE risk assessment models for hospitalised cancer patients undergoing chemotherapy at the tertiary oncology department in Poland: is pharmacological thromboprophylaxis overused? |
title_fullStr | The comparison between Caprini and Padua VTE risk assessment models for hospitalised cancer patients undergoing chemotherapy at the tertiary oncology department in Poland: is pharmacological thromboprophylaxis overused? |
title_full_unstemmed | The comparison between Caprini and Padua VTE risk assessment models for hospitalised cancer patients undergoing chemotherapy at the tertiary oncology department in Poland: is pharmacological thromboprophylaxis overused? |
title_short | The comparison between Caprini and Padua VTE risk assessment models for hospitalised cancer patients undergoing chemotherapy at the tertiary oncology department in Poland: is pharmacological thromboprophylaxis overused? |
title_sort | comparison between caprini and padua vte risk assessment models for hospitalised cancer patients undergoing chemotherapy at the tertiary oncology department in poland: is pharmacological thromboprophylaxis overused? |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909728/ https://www.ncbi.nlm.nih.gov/pubmed/29692661 http://dx.doi.org/10.5114/wo.2018.74391 |
work_keys_str_mv | AT łukaszukrobertf thecomparisonbetweencapriniandpaduavteriskassessmentmodelsforhospitalisedcancerpatientsundergoingchemotherapyatthetertiaryoncologydepartmentinpolandispharmacologicalthromboprophylaxisoverused AT dolnamichnojustyna thecomparisonbetweencapriniandpaduavteriskassessmentmodelsforhospitalisedcancerpatientsundergoingchemotherapyatthetertiaryoncologydepartmentinpolandispharmacologicalthromboprophylaxisoverused AT plenskrzysztof thecomparisonbetweencapriniandpaduavteriskassessmentmodelsforhospitalisedcancerpatientsundergoingchemotherapyatthetertiaryoncologydepartmentinpolandispharmacologicalthromboprophylaxisoverused AT czyzewiczgrzegorz thecomparisonbetweencapriniandpaduavteriskassessmentmodelsforhospitalisedcancerpatientsundergoingchemotherapyatthetertiaryoncologydepartmentinpolandispharmacologicalthromboprophylaxisoverused AT undasanetta thecomparisonbetweencapriniandpaduavteriskassessmentmodelsforhospitalisedcancerpatientsundergoingchemotherapyatthetertiaryoncologydepartmentinpolandispharmacologicalthromboprophylaxisoverused AT łukaszukrobertf comparisonbetweencapriniandpaduavteriskassessmentmodelsforhospitalisedcancerpatientsundergoingchemotherapyatthetertiaryoncologydepartmentinpolandispharmacologicalthromboprophylaxisoverused AT dolnamichnojustyna comparisonbetweencapriniandpaduavteriskassessmentmodelsforhospitalisedcancerpatientsundergoingchemotherapyatthetertiaryoncologydepartmentinpolandispharmacologicalthromboprophylaxisoverused AT plenskrzysztof comparisonbetweencapriniandpaduavteriskassessmentmodelsforhospitalisedcancerpatientsundergoingchemotherapyatthetertiaryoncologydepartmentinpolandispharmacologicalthromboprophylaxisoverused AT czyzewiczgrzegorz comparisonbetweencapriniandpaduavteriskassessmentmodelsforhospitalisedcancerpatientsundergoingchemotherapyatthetertiaryoncologydepartmentinpolandispharmacologicalthromboprophylaxisoverused AT undasanetta comparisonbetweencapriniandpaduavteriskassessmentmodelsforhospitalisedcancerpatientsundergoingchemotherapyatthetertiaryoncologydepartmentinpolandispharmacologicalthromboprophylaxisoverused |